Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 2, 2011, Pages 384-386

  Krug, Lee M ^a   Crawford, Jeffrey ^b   Ettinger, David S ^c   Shapiro, Geoffrey I ^d   Spigel, David ^e   Reiman, Tony ^f   Temel, Jennifer S ^g   Michelson, Glenn C ^h   Young, Donald Y ^h   Hoch, Ute ⁱ   Adelman, Daniel C ^j  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e SARAH CANNON RESEARCH INSTITUTE   (United States)

^f SAINT JOHN REGIONAL HOSPITAL   (Canada)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h Sunesis Pharmaceuticals Inc   (United States)

ⁱ NEKTAR THERAPEUTICS   (United States)

^j Alvine Pharmaceuticals Inc ^*  (United States)

more..

Author keywords

Phase II; Quinolone; Small cell lung cancer; Voreloxin

Indexed keywords

BEVACIZUMAB; CISPLATIN; ETOPOSIDE; IRINOTECAN; PACLITAXEL; TIRAPAZAMINE; VORELOXIN;

ADULT; ARTICLE; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONSTIPATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG RESPONSE; DRUG SENSITIVITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE; VOMITING;

EID: 79551547777     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318200e509     Document Type: Article

References (10)

1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-4544.
2. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441-5447.
3. Hawtin RE, Stockett DE, Byl JA, et al. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS One 2010;5: e10186.
4. Yamashita Y, Ashizawa T, Morimoto M, et al. Antitumor quinolones with mammalian topoisomerase II mediated DNA cleavage activity. Cancer Res 1992;52:2818-2822.
5. Hoch U, Lynch J, Sato Y, et al. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemother Pharmacol 2009;64:53-65.
6. Advani RH, Hurwitz HI, Gordon MS, et al. Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. Clin Cancer Res 2010;16:2167-2175.
7. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
8. Fleming TR. One sample multiple testing procedure for phase II clinical trials. Biometrics 1982;38:143-151.
9. Evanchik MJ, Allen D, Yoburn JC, et al. Metabolism of (+)-1, 4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl) -1, 8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent. Drug Metab Dispos 2009;37:594-601.
10. Hirte H, McGuire W, Edwards R, et al. Final results of a phase 2 study of voreloxin in women with platinum-resistant ovarian cancer. Proc Amer Soc Clin Oncol 2010:390s, abstract 5002.